RUO Labeling Requirements: What the Rule Says

Key takeaways

The exact sentence “For Research Use Only. Not for use in diagnostic procedures.” comes from 21 CFR 809.10(c), the labeling regulation for in vitro diagnostic products in the laboratory research phase.
A research peptide is not an in vitro diagnostic product, so that regulation does not require anything of it. Stores use the wording by convention, not by mandate.
That matters in both directions: there is no rule you are breaking by wording it differently, and no rule you are satisfying by wording it exactly.
FDA has taken the same position in the IVD context that it takes with peptides — a research-use statement does not settle intended use where the rest of the evidence points elsewhere.
The statement is still worth having, prominently and consistently, because a store that is genuinely for laboratory supply should say so everywhere a buyer looks.

What the regulation actually covers

Part 809 of Title 21 of the Code of Federal Regulations is titled “In Vitro Diagnostic Products for Human Use”. Section 809.10 sets out labeling requirements for those products, and paragraph (c) deals with products in the research and investigational phases of development.

Under 809.10(c)(2)(i), a product in the laboratory research phase of development, and not represented as an effective in vitro diagnostic product, must bear the statement, prominently placed: “For Research Use Only. Not for use in diagnostic procedures.” The parallel investigational statement is “For Investigational Use Only. The performance characteristics of this product have not been established.”

Two details are usually lost in reproduction. The phrase “prominently placed” is part of the requirement, not a suggestion. And the second sentence — “Not for use in diagnostic procedures” — exists because the product being described is a diagnostic reagent. It is answering a question a peptide vial was never asked.

Why a peptide store is borrowing, not complying

A vial of a synthesised peptide sold as laboratory material is not an in vitro diagnostic product. Nothing in Part 809 applies to it. When a research-supply store writes “For Research Use Only. Not for use in diagnostic procedures.” on a product page, it is adopting the most recognisable research-use formula in the regulations, not satisfying a rule.

This is worth being precise about, because a great deal of category advice presents the RUO statement as a compliance requirement that has been met. It has not been met, because it was never owed. The genuine legal exposure for a research peptide store sits with the drug definition in the FD&C Act, not with an IVD labeling regulation.

None of which makes the statement pointless. Borrowing a clear, widely understood sentence is better than inventing a vague one. It just does not do what a requirement does, and treating it as though it did is how stores end up with a carefully formatted label on a site that contradicts it.

Part 809 governs in vitro diagnostic products; a research peptide is not one.
There is no FDA-mandated wording for a research peptide’s research-use statement.
The wording most stores use is the IVD formula, quoted from 809.10(c)(2)(i).
The operative law for this category is the drug definition and the new drug approval requirement, not Part 809.

What FDA has said about the statement’s limits

Even inside the regulation’s own territory, the statement is not treated as controlling. FDA issued guidance in November 2013, from CDRH and CBER, on the distribution of in vitro diagnostic products labeled for research use only or investigational use only, addressing products carrying the correct label that were nevertheless being distributed for clinical use.

The principle is the one that runs through the peptide warning letters: a labeling statement is one piece of evidence about intended use, and it does not override what the manufacturer knows, promotes or arranges. In the peptide letters the same reasoning is stated bluntly — despite research-use statements on the labeling, website evidence established the products were intended as drugs for human use.

So the statement’s value is corroborative. On a store that is consistent with it, the statement summarises the truth. On a store that is not, it documents that the seller knew which question was being asked.

The other rules that do apply to the label

Dropping Part 809 does not leave the label unregulated, it moves the question elsewhere. A research-supply store is still selling a physical product into commerce, and several bodies of law reach the container regardless of the research-use statement.

Hazard communication is the usual one. If a material meets a hazard classification, OSHA’s Hazard Communication Standard at 29 CFR 1910.1200 governs container labels and safety data sheets for shipments to workplaces, including laboratories. Many suppliers provide an SDS for this reason, and a store reselling into laboratories is generally expected to pass it on.

Carrier and transport rules apply to how the parcel is packed and declared, and are set by the carrier and by transport regulation rather than by FDA. State weights-and-measures and consumer-protection rules reach net quantity and identity statements. None of these is satisfied or affected by the research-use sentence.

The practical consequence is that the label has several jobs. Identity, lot, size, supplier and hazard information are the parts with rules attached. The research-use statement is the part with a convention attached. Confusing the two is how a store ends up with a beautifully worded disclaimer and no lot number.

Product identity and net quantity, stated accurately and matching the record.
Lot or batch identifier, matching the certificate of analysis you publish.
Supplier or responsible-party identity and contact details.
Hazard information and a safety data sheet where the material is classified as hazardous.
The research-use statement, by convention, prominently and consistently.

Using the statement well

If you are going to carry a research-use statement, carry it properly. Prominence and consistency are what make it credible, and both are cheap.

Put it where a buyer forms an impression, not only where a lawyer would look: the entry acknowledgment, each product page near the buying controls, the cart or checkout, the terms of sale and order confirmations. Use the same wording every time — a store with four slightly different versions reads as a store that pasted them in.

Then audit against it. The statement is contradicted by outcome language in product copy, by human-use framing in email and ads, by reconstitution supplies in the catalog, by dosing tools and by reviews describing personal use. Any of those is louder than the sentence.

The research-use disclaimer template has short and full wordings and the placements that matter. Torva OS puts a 21+ research-use acknowledgment on every storefront, re-confirmed before checkout, and applies research-use wording to starter policies; you can preview it on your own catalog free, with no card.

Choose one wording and record it as the canonical version.
Place it on the entry gate, product pages, checkout, terms and order emails.
Search your own site for outcome language, human-use framing and dosing content, including text inside images.
Remove reconstitution supplies and dose calculators from the catalog and the site.
Re-audit whenever you add a compound, a page, a campaign or an affiliate.

Frequently asked questions

Is “For Research Use Only” legally required on a peptide?

No. That exact statement is required by 21 CFR 809.10(c)(2)(i) for in vitro diagnostic products in the laboratory research phase. A research peptide is not an in vitro diagnostic product, so the regulation does not apply to it and no specific wording is mandated.

Can I use different wording?

Yes, since no wording is required for this product category. Most stores use the IVD formula or a variation such as “for laboratory research use only; not for human or veterinary use” because it is widely recognised. What matters more than the exact words is that the statement is prominent, consistent and not contradicted elsewhere on the site.

Where should the statement appear?

Anywhere a buyer forms an impression of what the product is for: the entry acknowledgment, product pages near the buying controls, the cart or checkout, the terms of sale and order confirmations. A statement that appears only in a footer is doing very little.

Does the statement stop a product being treated as a drug?

No. Intended use is established from the whole presentation. FDA has repeatedly written to peptide vendors that despite research-use statements on their labeling, evidence obtained from their websites established the products were intended as drugs for human use.

Sources

Put the ideas to work.

Preview your store on Torva OS — no card needed — or explore the Desk demo, the eight themes and the plans. Questions: hello@torvaos.com.

General information for merchants, not legal, tax or financial advice. Check the rules in your jurisdiction and with your providers.